Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.

Carlo Antozzi,Tuan Vu,Sindhu Ramchandren,Richard J Nowak,Constantine Farmakidis,Vera Bril,Jan De Bleecker,Huan Yang,Eduard Minks,Jin-Sung Park,Mariusz Grudniak,Marek Smilowski,Teresa Sevilla,Sarah Hoffmann,Kumaraswamy Sivakumar,Yasushi Suzuki,Eriene Youssef,Panna Sanga,Keith Karcher,Yaowei Zhu,John J Sheehan,Hong Sun,Vivacity-Mg3 Study Group

doi:10.1016/s1474-4422(24)00498-8

Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.

Carlo Antozzi, Tuan Vu + Show 21 more

https://doi.org/10.1016/s1474-4422(24)00498-8

Copy DOI

Export

Save

Cite

Journal: The Lancet. Neurology	Publication Date: Feb 1, 2025
Citations: 1

#Myasthenia Gravis Activities Of Daily Living #Myasthenia Gravis Activities Of Daily Living Score #Generalised Myasthenia Gravis #Placebo Group #Least-squares Mean Change #Myasthenia Gravis #Open-label Extension Phase #Dose Of Study Drug #Burdensome Side-effects #Johnson Company

Abstract
Full-Text
Similar Papers

Abstract

Listen

Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: The Lancet. Neurology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.